Significant improvement in overall survival (OS) results seen in phase 3 TROPiCS study. Sacituzumab Govitecan improved OS from 11.2 months to 14.4 months compared to treatment of choice chemo.
My name is Sarah Delany. I'm a breast medical oncologist at Dana Farber Cancer Institute. And as for this year we saw results of tropics 02, which was a randomized Phase three study in patients with metastatic hormone receptor positive breast cancer who had received 2 to 4 prior lines of chemotherapy in the advanced disease setting. And compared Societa Samoa The Vatican to treatment of physicians choice chemotherapy. We have previously seen results suggesting that societies um have improved progression free survival compared to chemotherapy. But asthma, we are now seeing results from the overall survival data which suggested that societies move did improve overall survival from 11 0.2 months in the control arm to 14.4 months in the SAs sata Tzemach arm. So leading to a 3.2 month overall improvement in survival favoring SAS ATAS a mob. Societies have also improved response rates as well as prolonged median duration of response compared to standard chemotherapy. Again suggesting that society asthma is associated now with both improved progression free and overall survival and metastatic hormone receptor positive disease
